LUMPO
Liverpool Uveal Melanoma Prognosticator Online
A validated tool that estimates an individual patient’s risk of metastasis after treatment for uveal melanoma.
Research into eye cancer, from the laboratory to the clinic.
Pathologists, scientists, ophthalmologists and statisticians in Liverpool and London, working beside the Liverpool Ocular Oncology Centre since 2006.
For patients and families
Plain-language guides to the eye cancers we study, and where to find clinical and emotional support.
For researchers and clinicians
Molecular pathology, a dedicated tumour biobank and the LUMPO prognostic tool, built with the Liverpool Ocular Oncology Centre.
For supporters
Research into rare cancers depends on donations and on people who fundraise for us.
What we study
The group was founded by Professor Sarah Coupland and Professor Bertil Damato to study the biology of adult eye tumours and turn it into better prognosis, treatment and support.
- Uveal melanoma The most common primary eye cancer in adults, and the core of our work for over two decades.
- Conjunctival melanoma A rare melanoma of the eye’s surface, studied through pathology and molecular profiling.
- Ocular adnexal lymphoma Lymphomas of the tissues around the eye, a long-standing area of expertise.
- Molecular pathology Genetic analysis of tumours that informs prognosis and treatment.
- Ocular Oncology Biobank A curated collection of ocular tumour samples for translational research.
Tools built by the group
EYE-CAN-AID
Eye Cancer AI Database
A secure Trusted Research Environment giving approved researchers access to imaging, pathology and genetic data, with patient privacy at its core.
Recent papers
344 peer-reviewed papers since 2004, searchable by author, title and year.
Browse all publications
Fund research into rare eye cancers
Research into rare cancers relies on the generosity of supporters. Gifts go through the University of Liverpool and fund the group’s work.